S&P Futures
4,033.50 +32.00 (+0.80%) Dow Futures
32,764.00 +176.00 (+0.54%) Nasdaq Futures
12,841.75 +109.25 (+0.86%) Russell 2000 Futures
1,782.60 +17.80 (+1.01%) Crude Oil
73.82 +0.62 (+0.85%) Gold
1,962.60 -10.90 (-0.55%)
ARK Space Exploration & Innovation ETF (ARKX)
After hours:
| Previous Close | 13.47 |
| Open | 13.51 |
| Bid | 0.00 x 3000 |
| Ask | 0.00 x 1300 |
| Day's Range | 13.36 - 13.51 |
| 52 Week Range | 11.77 - 18.58 |
| Volume | |
| Avg. Volume | 54,325 |
| Net Assets | 63.34M |
| NAV | 20.23 |
| PE Ratio (TTM) | N/A |
| Yield | N/A |
| YTD Daily Total Return | N/A |
| Beta (5Y Monthly) | 0.00 |
| Expense Ratio (net) | 0.75% |
| Inception Date | 2021-03-30 |
- Yahoo Finance Video
Space: ‘There’s a huge market opportunity’ for some companies, strategist says
Space Capital Managing Partner Chad Anderson sits down with Yahoo Finance Live anchors to discuss whether the space industry is equipped to weather an economic downturn, SPAC activity, and investing opportunities in space-related assets.
- Yahoo Finance Video
Ark Invest’s Cathie Wood teases new crossover fund
Yahoo Finance's Alexandra Semenova discusses the anticipated new fund from Cathie Wood's Ark Invest that will blend assets in the private and public markets.
- GlobeNewswire
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Cambridge, MA U.S.A. (April 22, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that on April 20, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with requirements of Nas
